Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F21%3AN0000019" target="_blank" >RIV/00023728:_____/21:N0000019 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/21:10429371 RIV/00216208:11310/21:10429371

Result on the web

<a href="https://doi.org/10.1038/s41598-021-90973-2" target="_blank" >https://doi.org/10.1038/s41598-021-90973-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-021-90973-2" target="_blank" >10.1038/s41598-021-90973-2</a>

Result language

angličtina

Original language name

Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response

Original language description

Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p<0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naive patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30226 - Rheumatology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Scientific Reports

ISSN

2045-2322

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

11525

Country of publishing house

DE - GERMANY

Number of pages

10

Pages from-to

1-10

UT code for WoS article

000660844900050

EID of the result in the Scopus database

2-s2.0-85107358081